JP2020503363A - チューブリン結合化合物およびその治療的使用 - Google Patents

チューブリン結合化合物およびその治療的使用 Download PDF

Info

Publication number
JP2020503363A
JP2020503363A JP2019536967A JP2019536967A JP2020503363A JP 2020503363 A JP2020503363 A JP 2020503363A JP 2019536967 A JP2019536967 A JP 2019536967A JP 2019536967 A JP2019536967 A JP 2019536967A JP 2020503363 A JP2020503363 A JP 2020503363A
Authority
JP
Japan
Prior art keywords
atom
tubulin
compound
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503363A5 (enExample
Inventor
ファン，ラン
アンバダース ケードカル，サントッシュ
アンバダース ケードカル，サントッシュ
オー． スタインメッツ，マイケル
オー． スタインメッツ，マイケル
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド, ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2020503363A publication Critical patent/JP2020503363A/ja
Publication of JP2020503363A5 publication Critical patent/JP2020503363A5/ja
Priority to JP2022206294A priority Critical patent/JP2023027366A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)
JP2019536967A 2017-01-06 2018-01-05 チューブリン結合化合物およびその治療的使用 Pending JP2020503363A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022206294A JP2023027366A (ja) 2017-01-06 2022-12-23 チューブリン結合化合物およびその治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443247P 2017-01-06 2017-01-06
US62/443,247 2017-01-06
PCT/US2018/012668 WO2018129381A1 (en) 2017-01-06 2018-01-05 Tubulin binding compounds and therapeutic use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022206294A Division JP2023027366A (ja) 2017-01-06 2022-12-23 チューブリン結合化合物およびその治療的使用

Publications (2)

Publication Number Publication Date
JP2020503363A true JP2020503363A (ja) 2020-01-30
JP2020503363A5 JP2020503363A5 (enExample) 2021-04-30

Family

ID=62790877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536967A Pending JP2020503363A (ja) 2017-01-06 2018-01-05 チューブリン結合化合物およびその治療的使用
JP2022206294A Pending JP2023027366A (ja) 2017-01-06 2022-12-23 チューブリン結合化合物およびその治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022206294A Pending JP2023027366A (ja) 2017-01-06 2022-12-23 チューブリン結合化合物およびその治療的使用

Country Status (5)

Country Link
US (2) US11633393B2 (enExample)
EP (1) EP3565812B1 (enExample)
JP (2) JP2020503363A (enExample)
CN (1) CN110431135A (enExample)
WO (1) WO2018129381A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023027366A (ja) * 2017-01-06 2023-03-01 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20240091084A (ko) 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
US20210177952A1 (en) * 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
CA3137193A1 (en) * 2019-04-24 2020-10-29 The Governors Of The University Of Alberta Non-peptidic heterocycle-containing compounds for the treatment of alzheimer's disease
JP7749540B2 (ja) * 2019-09-05 2025-10-06 魯南製薬集団股▲分▼有限公司 Ｍａｇｌ阻害剤とその製造方法および使用
KR102304026B1 (ko) * 2020-02-03 2021-09-23 순천대학교 산학협력단 세포자멸사를 유도하는 치환된 아릴사이클로프로필우레아 화합물 및 이를 포함하는 항암용 조성물
TWI879949B (zh) * 2020-04-27 2025-04-11 南韓商奧土擇破利悟股份有限公司 用於ｕｂｒ盒結構域配體之化合物、組成物以及醫藥組成物
CN116568671A (zh) * 2020-10-16 2023-08-08 分子医学研究中心责任有限公司 杂环Cullin-RING泛素连接酶化合物及其用途
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN113750088B (zh) * 2021-09-16 2024-05-28 中国人民解放军海军特色医学中心 杂环化合物在制备治疗溃疡性结肠炎药物中的应用
WO2023203172A1 (en) * 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176372A1 (en) * 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2007035841A1 (en) * 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2016165007A1 (en) * 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK159770C (da) 1979-06-29 1991-04-22 Wellcome Found Analogifremgangsmaade til fremstilling af etherforbindelser eller farmakologisk acceptable salte deraf, samt ether-mellemprodukter til anvendelse som udgangsforbindelser ved fremgangsmaaden
EP0054924B1 (en) 1980-12-18 1986-08-06 The Wellcome Foundation Limited Pharmaceutical compounds, their preparation and use
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
ATE146075T1 (de) 1992-10-01 1996-12-15 Wellcome Found Tucaresol als mittel zur immunopotentierung
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
JP2002501944A (ja) 1998-01-29 2002-01-22 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド Ｎ−［（脂肪族又は芳香族）カルボニル］−２−アミノアセトアミド化合物及び環化化合物の製造方法
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
IL137974A0 (en) 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
WO2001053290A1 (en) 2000-01-18 2001-07-26 Nippon Steel Corporation Cell division inhibitors and process for producing the same
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
WO2001095858A2 (en) 2000-05-09 2001-12-20 Adpharma, Inc. Piperazinedione compounds
WO2002064592A1 (en) 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
RU2321396C2 (ru) 2002-05-17 2008-04-10 Авентис Фарма С.А. Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
MXPA05001217A (es) 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CA2553630A1 (en) 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
HRP20160757T1 (hr) 2004-04-19 2016-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Postupak za proizvodnju polimorfnog oblika i od klopidogrel-vodik-sulfata
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2129389B1 (en) 2007-02-15 2014-10-08 MannKind Corporation A method for enhancing t cell response
AU2008240117B2 (en) 2007-04-13 2013-12-05 Abraxis Bioscience, Llc SPARC and methods of use thereof
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
NZ586123A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2227296B1 (en) 2008-01-08 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
UA103221C2 (uk) 2009-01-16 2013-09-25 Тева Фармасьютікал Індастріз Лтд. Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
SG178828A1 (en) 2009-08-10 2012-04-27 Univ Texas Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
US20130225424A1 (en) 2010-03-03 2013-08-29 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20120214679A1 (en) 2010-11-29 2012-08-23 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
US20130072468A1 (en) * 2011-09-15 2013-03-21 Eric J. Gilbert Substituted piperazines as cb1 antagonists
CA2857191A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
LT2846809T (lt) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
AU2013308595C1 (en) 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014145642A2 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
JP6311097B2 (ja) 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
WO2015051543A1 (en) 2013-10-11 2015-04-16 Dalian Wanchun Biotechnology Co., Ltd. Cancer treatment with combination of plinabulin and taxane
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
ES2923942T3 (es) 2013-11-06 2022-10-03 Us Health Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
KR20170117113A (ko) 2015-02-12 2017-10-20 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
WO2017062505A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20240091084A (ko) 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP6779517B2 (ja) 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
JP2020503363A (ja) * 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
BR112019018880A2 (pt) 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
AU2019216305B2 (en) 2018-02-01 2024-11-21 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
WO2019194738A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
JP7500438B2 (ja) 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
US20210177952A1 (en) 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
CN113661253B (zh) 2018-11-14 2024-03-12 大连万春布林医药有限公司 微管蛋白结合剂治疗癌症的方法
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
US20230181605A1 (en) 2020-05-04 2023-06-15 Beyondspring Pharmaceuticals, Inc. Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176372A1 (en) * 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2007035841A1 (en) * 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2016165007A1 (en) * 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.76, Issue 14 Supplement, JPN6022006237, 2016, pages 1364, ISSN: 0004974586 *
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 14, no. 1, JPN6022006236, 2015, pages 141 - 147, ISSN: 0004974585 *
THE FEBS JOURNAL, vol. 283, JPN6022006239, 2016, pages 102 - 111, ISSN: 0004974587 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023027366A (ja) * 2017-01-06 2023-03-01 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用

Also Published As

Publication number Publication date
EP3565812C0 (en) 2023-12-27
US11633393B2 (en) 2023-04-25
US20200237754A1 (en) 2020-07-30
CN110431135A (zh) 2019-11-08
EP3565812B1 (en) 2023-12-27
US12458639B2 (en) 2025-11-04
US20240082243A1 (en) 2024-03-14
JP2023027366A (ja) 2023-03-01
EP3565812A1 (en) 2019-11-13
WO2018129381A1 (en) 2018-07-12
EP3565812A4 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
JP2023027366A (ja) チューブリン結合化合物およびその治療的使用
ES2960953T3 (es) Forma de sal de clorhidrato para la inhibición de EZH2
UA128369C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
KR20180002741A (ko) 키나제를 조절하는 화합물의 고형 형태
AU2013223713A1 (en) Oxazolidin- 2 -one compounds and uses thereof as PI3Ks inhibitors
US20240217922A1 (en) Modulators of sortilin activity
JP7744689B2 (ja) 脂質代謝関連疾患の予防又は治療用化合物
JP6192613B2 (ja) ニトリル誘導体ならびにそれらの薬学的使用および組成物
TW202208375A (zh) ４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
TW201924679A (zh) 抗腫瘤劑
JP2013545781A (ja) 二量体ｉａｐ阻害剤
US20230141981A1 (en) Novel compounds and composition for targeted therapy of kidney-associated cancers
EA022909B1 (ru) Соединение бензотиазолона
CN107849008B (zh) 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
JP2017523978A (ja) フマレート類似体および自己免疫疾患または炎症性疾患の治療におけるその使用
US10266490B2 (en) Radioprotector compounds
US10596168B2 (en) Antagonists of the thyroid-stimulating hormone receptor (TSHR)
US20240317762A1 (en) Phthalazinone-based parp-1 inhibitors
RU2753905C2 (ru) Твердые формы ингибитора ttk
WO2016180334A1 (zh) 双位点不可逆布鲁顿酪氨酸激酶抑制剂、组合物及其应用
US10689381B2 (en) Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance
PT1805169E (pt) Inibidores do receptor h3 de histamina, sua preparação e usos terapêuticos
US20250296955A1 (en) Pin1 targeting compounds and degraders and methods thereof
TWI905781B (zh) 脯胺醯羥化酶抑制劑及其用途
US20240366571A1 (en) Modulators of sk4 potassium channel and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221223

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230106

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230127

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250930